Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals: Director Gorjan Hrustanovic resigns from board, effective October 14, 2026

Neutral Impact 2 of 5 leadership Written later

Olema Pharmaceuticals director Dr. Gorjan Hrustanovic resigned from the board effective October 14, 2026, and from the Compensation and Science and Technology committees. The company said the resignation was not due to any disagreement over its operations, policies or practices. On October 15, 2026, the board appointed Dr. Prakash Raman to the Compensation and Science and Technology committees.

Key points

  • Dr. Gorjan Hrustanovic gave notice on October 12, 2026 and resigned from the board effective October 14, 2026
  • He also left the Compensation Committee and the Science and Technology Committee
  • The company said the resignation involved no disagreement on operations, policies or practices
  • Dr. Prakash Raman was appointed to the Compensation and Science and Technology committees effective October 15, 2026

The filing

CompanyOlema Pharmaceuticals, Inc. (OLMA)
Form8-K, current report
Filed with the SECOct 15, 2026, 5:00 PM ET
Accession number0001193125-26-423002

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.